Medicus Pharma gives Teverelix Phase 2 FDA update – ICYMI

Medicus Pharma (NASDAQ:MDCX) earlier this week outlined progress in the development of its investigational therapy Teverelix, confirming that it has submitted an optimized Phase 2 study design to the US Food and Drug Administration targeting acute urinary retention (AUR) relapse prevention. Speaking to Proactive, chief medical officer Dr Faisal Mehmud said the company is refining its clinical approach to improve both efficiency and speed of decision-making.